Treatment Recommendation for 14mm Prostate Cancer
For a 14mm prostate cancer lesion, the recommended treatment depends critically on the tumor's risk stratification (PSA level, Gleason/ISUP grade, clinical stage, and patient life expectancy), but this lesion size alone does not automatically determine therapy—you must complete full risk assessment first, then offer either active surveillance for low-risk disease, radical prostatectomy, or radiotherapy (with or without ADT) for intermediate-to-high risk disease based on the 2024 EAU guidelines 1.
Critical Context: Lesion Size Interpretation
The 14mm measurement is below the 15mm threshold that research identifies as a significant predictor of adverse pathology. Studies show that lesions ≥15mm independently predict extraprostatic extension (OR 7.94), positive margins (OR 7.86), and seminal vesicle invasion (OR 7.57) 2. Your 14mm lesion suggests potentially more favorable pathology, but this does NOT override standard risk stratification protocols.
Algorithmic Approach to Treatment Selection
Step 1: Complete Risk Stratification
You must determine:
- PSA level
- ISUP grade group (from biopsy)
- Clinical T-stage (DRE findings)
- MRI findings (PI-RADS score, extraprostatic extension)
- Patient life expectancy
Step 2: Treatment Based on Risk Category
If Low-Risk Disease (PSA <10, ISUP grade 1, cT1-T2a):
- Active surveillance is the strong recommendation for patients with >10 years life expectancy 1
- Requires MRI-guided confirmatory biopsy if not already performed
- Repeat biopsies at least every 3 years for 10 years
- Watchful waiting if life expectancy <10 years 1
If Intermediate-Risk Disease (PSA 10-20, ISUP grade 2-3, or cT2b-c):
For favorable intermediate-risk with low disease burden:
- Active surveillance is a weak recommendation for highly selected ISUP grade 2 patients (<10% pattern 4, PSA <10, cT2a, low MRI extent, ≤3 positive cores) 1
- Exclude patients with cribriform or intraductal histology (strong recommendation) 1
For definitive treatment:
- Radical prostatectomy with nerve-sparing if low risk of extracapsular disease (strong recommendation) 1
- OR IMRT/VMAT + IGRT (76-78 Gy or moderate hypofractionation) plus short-term ADT (4-6 months) (strong recommendation) 1
- OR LDR brachytherapy for favorable intermediate-risk with good urinary function (strong recommendation) 1
If High-Risk or Locally Advanced Disease (PSA >20, ISUP grade 4-5, or cT3-4):
- IMRT/VMAT + IGRT (76-78 Gy) plus long-term ADT (2-3 years) (strong recommendation) 1
- OR Radical prostatectomy as part of multimodal therapy with extended pelvic lymph node dissection 1
- For cN0M0 with 2+ high-risk factors: Add abiraterone for 2 years to RT + ADT (strong recommendation) 1
Critical Pitfalls to Avoid
Do NOT rely on lesion size alone: The 14mm measurement provides prognostic information but does not replace comprehensive risk stratification 2
Do NOT offer focal therapy outside clinical trials: Whole-gland or focal ablative therapies should only be offered within clinical trials or registries for intermediate-risk disease (strong recommendation) 1. While research shows focal therapy outcomes 3, 4, guidelines have not yet endorsed this as standard practice.
Do NOT exclude ISUP grade 3 from active surveillance: This is explicitly contraindicated (strong recommendation) 1
Do NOT perform treatment without MRI: If no prior MRI, perform before confirmatory biopsy (strong recommendation) 1
Quality of Life Considerations
- Radical prostatectomy: Risk of urinary incontinence and erectile dysfunction
- Radiotherapy: Risk of bladder/rectal inflammation, preserved continence typically better than surgery
- Active surveillance: Preserves quality of life but requires psychological tolerance of untreated cancer and commitment to monitoring
The 14mm lesion size suggests you may have more favorable pathology than larger lesions, but you must complete full staging and risk assessment before making definitive treatment recommendations.